Email: cspc@cspc.cn
News
News Center
Jul. 14
2026
VOLUNTARY ANNOUNCEMENT - DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) AND ANBENITAMAB (KN026) GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE FIRS
Jul. 07
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2070 INJECTION FOR THE TREATMENT OF MIXED HYPERLIPIDAEMIA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHI
Jul. 02
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL STUDY OF SYH2095 TABLETS AS A MONOTHERAPY OR IN COMBINATION REGIMENS FOR THE TREATMENT OF ADVANCED MALIGNANT TUMOURS O
VOLUNTARY ANNOUNCEMENT - RECOMBINANT HERPES ZOSTER VACCINE (SYS6052) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
VOLUNTARY ANNOUNCEMENT - IRON SUCROSE INJECTION RECEIVES MARKETING APPROVAL
VOLUNTARY ANNOUNCEMENT - SYS6043 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER, PRIMARY PERITONEAL CA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
